Lack of efficacy of topical cyclosporin A in atopic dermatitis and allergic contact dermatitis.
Since oral cyclosporin A (CsA) has demonstrated its effectiveness in psoriasis and atopic dermatitis, efforts have been made to develop a topical CsA formulation, thus avoiding systemic adverse events. A limited number of publications are available on the use of topical CsA in allergic contact dermatitis and atopic dermatitis. Moreover the response rate of humans to topical CsA is about 50% or less. We now report our results with three new topical CsA formulations on allergic contact dermatitis and atopic dermatitis. No significant improvement was found in 16 atopic dermatitis patients and 7 allergic contact dermatitis (nickel sulphate) patients.
De Rie
M A
MA
Department of Dermatology, University of Amsterdam, The Netherlands.
Meinardi
M M
MM
Bos
J D
JD
D000279:Administration, Cutaneous; D016572:Cyclosporine / Q000008:administration & dosage*; D003876:Dermatitis, Atopic / Q000139:chemically induced / Q000188:drug therapy*; D003877:Dermatitis, Contact / Q000188:drug therapy* / Q000209:etiology; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D006801:Humans; D009532:Nickel / Q000009:adverse effects*; D009824:Ointments; D012867:Skin / Q000187:drug effects*; D013535:Suspensions
D009824:Ointments; D013535:Suspensions; C029938:nickel sulfate; D009532:Nickel; D016572:Cyclosporine